Advanced search
Publication Cover
Acta Clinica Belgica
International Journal of Clinical and Laboratory Medicine
Volume 60, 2005 - Issue 6
Submit an article Journal homepage
24
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

ECONOMIC EVALUATIONS OF PNEUMOCOCCAL VACCINATION STRATEGIES IN ADULTS. A SUMMARY OF THE RESULTS.

N. ThiryCentre for the Evaluation of Vaccination, Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein 1, 2610Antwerp, BelgiumCorrespondence[email protected]
,
P. BeutelsCentre for the Evaluation of Vaccination, Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein 1, 2610Antwerp, Belgium;National Centre for Immunisation Research and Surveillance (NCIRS), Royal Alexandra Hospital for Children, University of Sydney, Locked Bag 4001, Westmead, NSW 2145, Australia;Centre for Health Economics Research and Evaluation (CHERE), University of Technology, Sydney, P.O. Box 123, Broadway, NSW 2007, Australia
&
P. Van DammeCentre for the Evaluation of Vaccination, Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein 1, 2610Antwerp, Belgium
Pages 338-344 | Published online: 09 Jan 2014

REFERENCES

  • Belgian High Council of Public Health. Opinions and brochures. Anti-pneumococcal vaccination (2002) (online). Available from URL: http://www.healthlgov.be/CSH_HGR/Francais/Brochures/fr2002_pneumocoque.pdf ( Accessed 2004 Oct 2004)
  • Beutels P and Postma M. Economic evaluations of adult pneumo-coccal vaccination strategies. Expert Rev. Pharmacoeconomics Outcomes Res 2001; 1(1): 89–100.
  • Vold Pepper P, Owens DK. Cost-effectiveness of the pneumococ-cal vaccine in healthy younger adults. Med Decis Making 2002; 22 (5 Suppl): S45–57.
  • Postma MJ, Heijnen M-LA, Beutels Petal. Farmaco-economi-sche aspecten van vaccinatie tegen invasieve pneumokokkenin-fecties bij 65-plussers; literatuuroverzicht van kosteneffectiviteits analysen. Ned Tijdschr Geneesk 2002: 146 (18): 855–9.
  • Ament A, Fedson DS, Christie P. Pneumococcal vaccination andpneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis 2001; 33 (12): 2078–9.
  • Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysac-charide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. European Journal of Epidemiology 2004; 19: 365–75.
  • Sisk JE, Whang W, Butler JC et al. Cost-effectiveness of vac-cination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138 (12): 960–8.
  • Ament A, Baltussen R, Durur G et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000; 31: 444–50.
  • De Graeve D, Lombaert G and Goossens H. Cost-effectivenessanalysis of pneumococcal vaccination of adults and elderly per-sons in Belgium. Pharmacoeconomics 2000; 17(6):591–601.
  • Sisk JE, Moskowitz AJ, Whang W et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278 (16): 1333–9.
  • Melegaro A, Edmunds WJ. The 23-valent pneumococcal po-lysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses. European Journal of Epidemiology 2004; 19: 353–63.
  • Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccine. Vaccine 2003; 21: 1769–75.
  • Gasparini R, Lucioni C, Lai P et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 2002; 20: B50–B54.
  • W.E. Peetermans, N. Van de Vyver, Y. Van Laethem et al. Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: A Belgian Consensus Report. Acta Clinica Belgica, In this issue.
  • Beutels P, Van Doorslaer E, Van Damme P etal. Methodological issues and new developments in the economic evaluation of vac-cines. Expert Rev Vaccines. 2003;2 (5): 649–60.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.